Skip to main content

Table 3 Cost estimates for cost-effectiveness analysis of NAC and AC

From: Cost-effectiveness analysis of neoadjuvant versus adjuvant chemotherapy for cT2-4N0-1 non-small cell lung cancer patients during initial treatment phase

Event NAC AC Source
Surgerya 2351.96 2367.82 MPFS [30]
Additional surgical proceduresa 1854.46 2513.65
Hospitalization
 With ≥ 3 complication 96,462 96,462 Xin et al. [27]
 Without ≥ 3 complication 66,800 66,800
Chemotherapy (4 cycles) 30,946.5 30,946.5 Local charge [30]
Imaging 6036 3568 Local charge [30]
≥ 3 grade chemotherapy adverse event treatmentb 3679.8 3679.8 CTCAE [28]
CSCO [29]
  1. aCost was calculated as the weighted average of results reported in Brandt et al. [10]; see Additional file 1: Table S1 for individual procedures and probabilities
  2. bCost was calculated as the weighted average of results reported in NATCH [3]; see Additional file 2: Table S2 for individual procedures and probabilities